A-I

General Information


DRACP ID  DRACP01981

Peptide Name   A-I

Sequence  AIIKKIIKKIIKKI

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Jurkat Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50=25 µM MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 10% Hemolysis=500 µM

Normal (non-cancerous) Cytotoxicity  Human chondrocytes-articular cells Hca: 25% Killing=40 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01981

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C81H156N20O15

Absent amino acids  CDEFGHLMNPQRSTVWY

Common amino acids  I

Mass  188234

Pl  11.5

Basic residues  6

Acidic residues  0

Hydrophobic residues  8

Net charge  6

Boman Index  295

Hydrophobicity  70.71

Aliphatic Index  202.14

Half Life 
  Mammalian:
  Yeast:
  E.coli:

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27644109

Title  Surface Physical Activity and Hydrophobicity of Designed Helical Peptide Amphiphiles Control Their Bioactivity and Cell Selectivity

Doi 10.1021/acsami.6b08297

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_14055

DRACP is developed by Dr.Zheng's team.